News & Press Releases
For all media inquiries, please contact us.
Smoking Cessation App-Maker Partners with GSK to Offer Nicotine Patches.
Digital smoking cessation company 2Morrow has partnered with GlaxoSmithKline, makers of Nicoderm patches, to offer the company’s Nicoderm CQ Patch to smokers who complete 2morrow’s cessation program.
Digital smoking cessation company 2Morrow has partnered with GlaxoSmithKline, makers of Nicoderm patches, to offer the company’s Nicoderm CQ Patch to smokers who complete 2morrow’s cessation program.
SmartQuit and GSK Collaborate to Provide NRT to App Users
2Morrow Inc, makers of SmartQuit®, the first clinically proven app to help smokers quit, announced their collaboration with GlaxoSmithKline® to provide nicotine replacement therapy (NRT) to program participants.
2Morrow Inc, makers of SmartQuit®, the first clinically proven app to help smokers quit, announced their collaboration with GlaxoSmithKline® (LSE/NYSE:GSK) to provide nicotine replacement therapy (NRT) to program participants.
SmartQuit is an app-based program first developed by researchers at the Fred Hutchinson Cancer Research Center and has been tested in 2 clinical trials.* The program uses a unique Acceptance and Commitment Therapy (ACT) approach to help participants learn new ways to deal with the urge to smoke. In clinical trials, without NRT, smokers who used SmartQuit quit at rates that were 2-3 times higher than people trying on their own. SmartQuit is designed to use with or without quit medications such as the nicotine patch.
“We know that combining behavioral programs like SmartQuit and NRT can increase a smoker's chances of quitting,” says Jo Masterson, COO of 2Morrow. “Our clients have been asking us to make it easier for smokers to get NRT with the SmartQuit program and this GSK collaboration will do that.”
Most SmartQuit programs are offered by states, wellness programs or employers. Now those groups will be able to offer NRT to smokers via the app, increasing their odds of quitting.
About GSK Consumer Healthcare.
GSK Consumer Healthcare is one of the world's largest consumer healthcare companies. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products. We have a heritage that goes back over 160 years. We own some of the world’s best loved healthcare brands, including Sensodyne®, Theraflu®, Excedrin®, Nicorette® and NicoDerm® CQ®, Flonase®, and TUMS®. These brands are successful in over 100 countries around the world because they all show our passion for quality, guaranteed by science. They are inspired by the real wants and needs of the millions of people who walk into pharmacies, supermarkets, market stalls and go on-line all over the world every day, and choose us first.
Our goal is to build a global, growing business we call a Fast Moving Consumer Healthcare (FMCH) company, dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.
China's First Lady Visits Fred Hutch, Talks to Dr. Bricker About Smoking Cessation and SmartQuit
China’s first lady, Peng Liyuan, focused attention on the global-health problems of HIV infection and tobacco use during a hush-hush visit Wednesday to a Seattle cancer center.
Peng Liyuan, wife of Chinese President Xi Jinping, toured Fred Hutch to view advances in research on HIV/AIDS and smoking cessation. The first lady is a WHO goodwill ambassador.
Kirkland Smoking Cessation Startup Teams With mHealth Technologies to Help Turkish Smokers Quit
China’s first lady, Peng Liyuan, focused attention on the global-health problems of HIV infection and tobacco use during a hush-hush visit Wednesday to a Seattle cancer center.
2Morrow, a startup that developed the first smartphone app proven in a clinical trial to help smokers quit their habits, is teaming up with Johnson City, Tennessee-based mHealth Technologies to help 100,000 people in Turkey quit smoking over the next three years.
North American Quitline Consortium 2015 Conference
Jo Masterson, COO of 2Morrow and Joella Pyatt of WA DOH will be presenting. Using Apps to Help Smokers Quit: Some Research, Data, and Real-world Applications.
Jo Masterson, COO of 2Morrow and Joella Pyatt of WA DOH will be presenting. Using Apps to Help Smokers Quit: Some Research, Data, and Real-world Applications.
SmartQuit App Gets $3.1M From National Cancer Institute for Large Smoking-Cessation Trial
The National Cancer Institute has awarded a $3.1 million, five-year grant to Dr. Jonathan Bricker, a behavioral scientist at Seattle’s Fred Hutchinson Cancer Research Center and the University of Washington, to conduct a large-scale clinical trial for the SmartQuit smoking-cessation app.
The National Cancer Institute has awarded a $3.1 million, five-year grant to Dr. Jonathan Bricker, a behavioral scientist at Seattle’s Fred Hutchinson Cancer Research Center and the University of Washington, to conduct a large-scale clinical trial for the SmartQuit smoking-cessation app.
Fred Hutch Scientist Gets $3.1M for Stop-Smoking App
A Seattle smoking-cessation researcher has received a $3.1 million, five-year grant from the National Cancer Institute to conduct a gold-standard trial of a promising stop-smoking app. The new trial follows a pilot study of SmartQuit conducted in collaboration with the University of Washington and 2Morrow Mobile.
A Seattle smoking-cessation researcher has received a $3.1 million, five-year grant from the National Cancer Institute to conduct a gold-standard trial of a promising stop-smoking app. The new trial follows a pilot study of SmartQuit conducted in collaboration with the University of Washington and 2Morrow Mobile.
2Morrow Recruiting for Second Clinical Trial of Smoking Cessation App Program with Employers
A Seattle smoking-cessation researcher has received a $3.1 million, five-year grant from the National Cancer Institute to conduct a gold-standard trial of a promising stop-smoking app. The new trial follows a pilot study of SmartQuit conducted in collaboration with the University of Washington and 2Morrow Mobile.
2Morrow is embarking on a second study for a smoking cessation smartphone app it created with the Fred Hutchinson Cancer Center. It follows a clinical trial last year that showed higher quit rates than for Quitguides distributed by state programs, health plans and employers.
The second study is supported by a grant from the Life Sciences Discovery Fund and will evaluate the app’s effectiveness among employers following modifications to the program features.
